Glucagon-like peptide-1 receptor agonists (GLP 1 RA)
Glucagon-like peptide-1 receptor agonists (GLP 1 RA) is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 2 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
0
Mid Stage
0
Late Stage
Highest Phase Reached
Early Phase 1Trial Status & Enrollment
100.0%
2 of 2 finished
0.0%
0 ended early
1
trials recruiting
4
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Transformative Research in Diabetic Nephropathy 2.0
Optimization of Obesity for Total Knee Replacement With Glucagon-like Peptide-1 Receptor Agonist
Strict Weight Management Based on GLP-1 RA for Ablation Outcomes in Overweight or Obese Patients with T2DM and AF
An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice
Clinical Trials (4)
Transformative Research in Diabetic Nephropathy 2.0
Optimization of Obesity for Total Knee Replacement With Glucagon-like Peptide-1 Receptor Agonist
Strict Weight Management Based on GLP-1 RA for Ablation Outcomes in Overweight or Obese Patients with T2DM and AF
An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4